Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 438.27B | 435.08B | 426.68B | 335.14B | 297.18B |
Gross Profit | 370.26B | 369.09B | 364.44B | 279.72B | 244.65B |
EBITDA | 230.71B | 186.70B | 176.41B | 143.42B | 158.67B |
Net Income | 170.43B | 162.03B | 184.97B | 114.19B | 111.86B |
Balance Sheet | |||||
Total Assets | 1.54T | 1.42T | 1.31T | 1.15T | 998.99B |
Cash, Cash Equivalents and Short-Term Investments | 374.80B | 358.09B | 563.36B | 465.18B | 418.32B |
Total Debt | 21.88B | 11.62B | 9.41B | 6.67B | 7.99B |
Total Liabilities | 172.85B | 164.36B | 189.92B | 157.32B | 134.44B |
Stockholders Equity | 1.36T | 1.24T | 1.10T | 975.66B | 846.11B |
Cash Flow | |||||
Free Cash Flow | 178.33B | 126.02B | 140.68B | 70.50B | 76.09B |
Operating Cash Flow | 195.46B | 154.28B | 177.87B | 102.07B | 109.04B |
Investing Cash Flow | -129.07B | 5.92B | -48.29B | -96.20B | -5.26B |
Financing Cash Flow | -51.92B | -126.85B | -84.12B | -36.62B | -43.89B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | ¥2.24T | 12.72 | 12.99% | 2.27% | 0.73% | 7.75% | |
64 Neutral | ¥343.99B | 10.61 | -2.88% | 2.57% | 11.80% | -6.84% | |
$2.58B | 17.67 | 13.50% | ― | ― | ― | ||
$8.00B | 26.03 | 5.34% | 3.82% | ― | ― | ||
$2.04B | 14.41 | 7.90% | 0.01% | ― | ― | ||
$48.51B | 66.29 | 1.50% | 4.40% | ― | ― | ||
$1.85B | 8.65 | 11.16% | 3.74% | ― | ― |
Shionogi & Co., Ltd. has submitted a supplemental New Drug Application in Japan to expand the use of its oral antiviral drug, ensitrelvir, for treating COVID-19 in pediatric patients aged 6 years and older. This move follows positive Phase 3 study results showing the drug’s safety and efficacy in children, and if approved, it will address the unmet need for oral antiviral treatments in this age group. Ensitrelvir, also known as Xocova® in some markets, has already received emergency and full regulatory approval in Japan and is under review in other regions. The drug has shown promising results in preventing symptomatic COVID-19 in post-exposure scenarios, marking a significant step in Shionogi’s efforts to strengthen its position in the antiviral market.
The most recent analyst rating on (JP:4507) stock is a Hold with a Yen7400.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
Shionogi & Co., Ltd. announced the successful completion of its tender offer for shares of Torii Pharmaceutical Co., Ltd., which will become an equity-method affiliate of Shionogi as of June 25, 2025. This acquisition is expected to enhance Shionogi’s market position and expand its influence in the pharmaceutical industry, potentially impacting stakeholders by increasing the company’s operational scope and strategic capabilities.
The most recent analyst rating on (JP:4507) stock is a Hold with a Yen2750.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
Shionogi & Co., Ltd. announced the disposal of 200,400 treasury shares as part of a restricted stock compensation plan aimed at incentivizing directors and corporate officers to enhance corporate value. This move, approved by the Board of Directors, aligns with the company’s strategy to promote shared values with shareholders and adapt its governance structure, potentially impacting its market positioning and stakeholder relations.
The most recent analyst rating on (JP:4507) stock is a Hold with a Yen2750.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
Shionogi & Co., Ltd. announced an amendment to its tender offer for shares of Torii Pharmaceutical Co., Ltd. due to a patent infringement lawsuit involving Torii’s oral antipruritus medication, REMITCH®. Despite the legal proceedings, Torii’s stance on the tender offer remains unchanged, as the financial implications of the lawsuit are still uncertain.
The most recent analyst rating on (JP:4507) stock is a Hold with a Yen2750.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
Shionogi & Co., Ltd. announced the acceptance of its New Drug Application for naldemedine, a treatment for opioid-induced constipation, in China. This approval is expected to enhance pain management options in China, where current treatments are limited, and improve the quality of life for patients. The drug, already available in several regions, demonstrated significant efficacy in a Phase III trial in China. Following approval, Shionogi China Co., Ltd. will handle sales through an exclusive agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd., potentially boosting Shionogi’s market presence and revenue in China.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen3100.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
Shionogi & Co., Ltd. has announced amendments to its tender offer for shares of Torii Pharmaceutical Co., Ltd., following a notice from the Japan Fair Trade Commission. These amendments, which do not alter the terms of purchase, are necessary to update the Tender Offer Statement and ensure compliance with regulatory requirements, reflecting the company’s commitment to adhere to legal standards in its acquisition efforts.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen3100.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
Shionogi & Co., Ltd. announced its decision to propose amendments to its Articles of Incorporation at the upcoming Annual General Meeting of Shareholders. The amendments aim to transition the company to a structure with an Audit and Supervisory Committee, enhancing corporate governance and facilitating strategic decision-making. This move is expected to strengthen oversight, promote globalization, and support business model transformation, potentially impacting the company’s operational efficiency and stakeholder engagement.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen3100.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
Shionogi & Co., Ltd. reported its consolidated financial results for the fiscal year 2024, showing a slight increase in revenue and operating profit compared to the previous year. The company conducted a 3-for-1 stock split effective October 2024, which impacted earnings per share calculations. Despite a decline in comprehensive income, the company forecasts significant growth in revenue and profit for the fiscal year ending March 2026, indicating a positive outlook for stakeholders.
Shionogi & Co., Ltd. has announced the commencement of a tender offer to acquire all shares of TORII PHARMACEUTICAL CO., LTD., aiming to make it a wholly-owned subsidiary. This strategic move is part of a broader transaction involving stock consolidation and capital restructuring, which is expected to enhance Shionogi’s market position and operational capabilities by integrating TORII’s resources and expertise.
Shionogi & Co., Ltd. announced a strategic move to acquire the pharmaceutical business of Japan Tobacco Inc. and make Akros Pharma Inc. a sub-subsidiary, enhancing its capabilities in small molecule drug discovery. This transaction aligns with Shionogi’s vision of creating a new healthcare platform and aims to accelerate the development of innovative drugs, strengthen its global market position, and contribute to global health by delivering advanced pharmaceuticals.
Shionogi & Co. announced an increase in its dividend forecasts for the fiscal year ending March 31, 2025, reflecting its commitment to shareholder returns and corporate value growth. The company has achieved revenue stability in its domestic market through its respiratory infection treatments and is expanding its global presence with Cefiderocol. Additionally, Shionogi is advancing its COVID-19 treatment, Ensitrelvir, through clinical trials and regulatory discussions, while benefiting from increased royalties from its HIV franchise. The dividend increase is part of Shionogi’s strategy to enhance shareholder value, supported by its strong financial performance and strategic investments.